{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:50:04Z","timestamp":1792007404358,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["KWF: EMCR 2014-6340"],"award-info":[{"award-number":["KWF: EMCR 2014-6340"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Almost half of patients with colorectal liver metastases (CRLM) experience disease recurrence within one year after treatment with curative intent. To improve treatment, upfront identification of patients with CRLM at high risk of rapid disease recurrence is crucial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort-study, pretreatment ctDNA levels were determined by the modified fast aneuploidy screening test-sequencing system (mFast-SeqS) in 182 patients with resectable CRLM who did not receive perioperative chemotherapy. Resulting aneuploidy scores were dichotomized using a predefined threshold and associated with clinical outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 182 analysed patients, 34 (19%) were classified as ctDNA high and 156 (81%) as ctDNA low. Recurrence-free (RFS) and overall survival (OS) were shorter in the ctDNA high versus low group, with 1-year RFS of 29% versus 52%, and 3-year OS of 48% versus 78% respectively (log-rank P = 0.029 and &amp;lt; 0.001 respectively). The cumulative incidence of multiorgan recurrence within the first year after local treatment was significantly higher in ctDNA-high patients (Gray\u2019s test P &amp;lt; 0.001). Multivariable Cox regression analysis revealed that the aneuploidy score is independently associated with RFS (HR = 1.94; 95% c.i. 1.19 to 3.18) and multiorgan RFS up to 1 year (HR = 2.56; 95% c.i. 1.41 to 4.65) and OS up to 3 years (HR = 3.28; 95% c.i. 1.79 to 6.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study shows that mFast-SeqS provides an affordable and minimally invasive test for the upfront recognition of patients with CRLM at increased risk of rapid (multiorgan) disease recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjs\/znaf295","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T12:46:15Z","timestamp":1766666775000},"source":"Crossref","is-referenced-by-count":2,"title":["Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-na\u00efve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort"],"prefix":"10.1093","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8150-6040","authenticated-orcid":false,"given":"Lissa","family":"Wullaert","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1323-7054","authenticated-orcid":false,"given":"Lotte","family":"van Leeuwen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]},{"name":"Department of Clinical Genetics, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"de Weerd","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Van","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco","family":"Kraan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-9804","authenticated-orcid":false,"given":"Maurice P H M","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W M","family":"Martens","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-6002","authenticated-orcid":false,"given":"Dirk J","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M W","family":"Verheul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9980-8613","authenticated-orcid":false,"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia M","family":"Wilting","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026041703512783700_znaf295-B1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.ejso.2021.12.004","article-title":"Treatment of metachronous colorectal cancer metastases in the Netherlands: a population-based study","volume":"48","author":"Meyer","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"2026041703512783700_znaf295-B2","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.hpb.2022.04.006","article-title":"Interregional practice variations in the use of local therapy for synchronous colorectal liver metastases in the Netherlands","volume":"24","author":"Meyer","year":"2022","journal-title":"HPB (Oxford)"},{"key":"2026041703512783700_znaf295-B3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","article-title":"Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases","volume":"32","author":"van der Geest","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"2026041703512783700_znaf295-B4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases\u2014a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"key":"2026041703512783700_znaf295-B5","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026041703512783700_znaf295-B6","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.21.01032","article-title":"Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial","volume":"39","author":"Kanemitsu","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026041703512783700_znaf295-B7","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2006.06.8353","article-title":"Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial","volume":"24","author":"Portier","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026041703512783700_znaf295-B8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","article-title":"ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal\u2013Anal Task Forces whitepaper","volume":"17","author":"Dasari","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041703512783700_znaf295-B9","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.21.02615","article-title":"Using circulating tumor DNA in colorectal cancer: current and evolving practices","volume":"40","author":"Malla","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041703512783700_znaf295-B10","doi-asserted-by":"crossref","first-page":"103406","DOI":"10.1016\/j.eclinm.2025.103406","article-title":"Circulating tumour cells & circulating tumour DNA in patients with resectable colorectal liver metastases (MIRACLE): a prospective, observational biomarker study","volume":"87","author":"Wullaert","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026041703512783700_znaf295-B11","doi-asserted-by":"crossref","first-page":"101951","DOI":"10.1016\/j.ctrv.2019.101951","article-title":"Whole exome sequencing of cell-free DNA\u2014a systematic review and Bayesian individual patient data meta-analysis","volume":"83","author":"Bos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2026041703512783700_znaf295-B12","doi-asserted-by":"crossref","first-page":"162ra54","DOI":"10.1126\/scitranslmed.3004742","article-title":"Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing","volume":"4","author":"Leary","year":"2012","journal-title":"Sci Transl Med"},{"key":"2026041703512783700_znaf295-B13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2024.08.2240","article-title":"Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY","volume":"35","author":"Kataoka","year":"2024","journal-title":"Ann Oncol"},{"key":"2026041703512783700_znaf295-B14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","article-title":"Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study","volume":"34","author":"Reichert","year":"2023","journal-title":"Ann Oncol"},{"key":"2026041703512783700_znaf295-B15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1373\/clinchem.2014.234286","article-title":"Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach","volume":"61","author":"Belic","year":"2015","journal-title":"Clin Chem"},{"key":"2026041703512783700_znaf295-B16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41523-023-00563-w","article-title":"Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival","volume":"9","author":"Verschoor","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"2026041703512783700_znaf295-B17","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/1878-0261.13449","article-title":"mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer","volume":"17","author":"Isebia","year":"2023","journal-title":"Mol Oncol"},{"key":"2026041703512783700_znaf295-B18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3390\/cancers11081171","article-title":"Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment","volume":"11","author":"Suppan","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026041703512783700_znaf295-B19","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/1878-0261.13196","article-title":"Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer","volume":"16","author":"Mendelaar","year":"2022","journal-title":"Mol Oncol"},{"key":"2026041703512783700_znaf295-B20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1878-0261.12037","article-title":"Application of circulating tumor DNA in prospective clinical oncology trials\u2014standardization of preanalytical conditions","volume":"11","author":"van Dessel","year":"2017","journal-title":"Mol Oncol"},{"key":"2026041703512783700_znaf295-B21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2049-2618-2-6","article-title":"An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform","volume":"2","author":"Fadrosh","year":"2014","journal-title":"Microbiome"},{"key":"2026041703512783700_znaf295-B22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"2026041703512783700_znaf295-B23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"2026041703512783700_znaf295-B24","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/ans.17835","article-title":"Recurrence patterns predict survival after resection of colorectal liver metastases","volume":"92","author":"Wong","year":"2022","journal-title":"ANZ J Surg"},{"key":"2026041703512783700_znaf295-B25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-022-01710-w","article-title":"Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance","volume":"22","author":"Stejskal","year":"2023","journal-title":"Mol Cancer"},{"key":"2026041703512783700_znaf295-B26","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1200\/JCO.2025.43.16_suppl.3561","article-title":"Prognostic factors of survival and recurrence after liver transplantation for unresectable colorectal liver metastases: results from the TransMet trial","volume":"43","author":"Adam","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026041703512783700_znaf295-B27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ijc.34255","article-title":"Sex differences in metastatic surgery following diagnosis of synchronous metastatic colorectal cancer","volume":"152","author":"Ljunggren","year":"2023","journal-title":"Int J Cancer"},{"key":"2026041703512783700_znaf295-B28","doi-asserted-by":"crossref","first-page":"101505","DOI":"10.1016\/j.jhepr.2025.101505","article-title":"Sex-based differences in survival after liver transplantation for colorectal cancer liver metastases: a multivariable analysis","volume":"7","author":"Vitale","year":"2025","journal-title":"JHEP Rep"},{"key":"2026041703512783700_znaf295-B29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/SLA.0000000000005461","article-title":"Prospective study of perioperative circulating tumor DNA dynamics in patients undergoing hepatectomy for colorectal liver metastases","volume":"277","author":"Newhook","year":"2023","journal-title":"Ann Surg"},{"key":"2026041703512783700_znaf295-B30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/cells8060516","article-title":"Circulating tumor cells and circulating tumor DNA detection in potentially resectable metastatic colorectal cancer: a prospective ancillary study to the Unicancer Prodige-14 trial","volume":"8","author":"Bidard","year":"2019","journal-title":"Cells"},{"key":"2026041703512783700_znaf295-B31","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.3390\/cancers12092434","article-title":"The level of preoperative plasma KRAS mutations and CEA predict survival of patients undergoing surgery for colorectal cancer liver metastases","volume":"12","author":"Polivka","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026041703512783700_znaf295-B32","doi-asserted-by":"crossref","first-page":"LBA3502","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3502","article-title":"Primary outcome analysis of the ORCHESTRA trial: a randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer","volume":"42","author":"Gootjes","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026041703512783700_znaf295-B33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/bjs.10572","article-title":"Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases","volume":"104","author":"Zhao","year":"2017","journal-title":"Br J Surg"},{"key":"2026041703512783700_znaf295-B34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1470-2045(14)70105-6","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial","volume":"15","author":"Primrose","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026041703512783700_znaf295-B35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/113\/4\/znaf295\/68100540\/znaf295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/113\/4\/znaf295\/68100540\/znaf295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:51:47Z","timestamp":1776412307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znaf295\/8650560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,4,9]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znaf295","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]},"article-number":"znaf295"}}